Eversept Partners LP Purchases New Stake in Pharvaris N.V. $PHVS

Eversept Partners LP purchased a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 439,177 shares of the company’s stock, valued at approximately $12,187,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Boothbay Fund Management LLC raised its position in shares of Pharvaris by 16.2% during the 4th quarter. Boothbay Fund Management LLC now owns 157,117 shares of the company’s stock valued at $4,360,000 after acquiring an additional 21,936 shares in the last quarter. ADAR1 Capital Management LLC raised its position in shares of Pharvaris by 150.6% during the 4th quarter. ADAR1 Capital Management LLC now owns 85,528 shares of the company’s stock valued at $2,373,000 after acquiring an additional 51,404 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Pharvaris during the 4th quarter valued at approximately $2,341,000. Jump Financial LLC acquired a new stake in shares of Pharvaris during the 4th quarter valued at approximately $730,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Pharvaris by 15.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 941,605 shares of the company’s stock valued at $26,130,000 after acquiring an additional 124,797 shares in the last quarter.

Insider Buying and Selling

In other news, Director Robert Glassman sold 10,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $29.82, for a total value of $298,200.00. Following the completion of the transaction, the director owned 10,500 shares of the company’s stock, valued at approximately $313,110. This represents a 48.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Peng Lu sold 15,000 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.24, for a total value of $453,600.00. Following the completion of the transaction, the insider directly owned 66,083 shares of the company’s stock, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 214,909 shares of company stock valued at $6,421,745. Company insiders own 11.84% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PHVS shares. Wolfe Research initiated coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Royal Bank Of Canada dropped their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a research report on Tuesday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.18.

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $33.41 on Thursday. Pharvaris N.V. has a 1-year low of $16.00 and a 1-year high of $33.50. The business’s fifty day moving average price is $29.81 and its two-hundred day moving average price is $27.67. The firm has a market capitalization of $2.19 billion, a PE ratio of -10.51 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. Equities research analysts expect that Pharvaris N.V. will post -3.22 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.